Introduction
FLT3 is a member of the class III receptor tyrosine kinase family and plays an important role in regulating the proliferation, differentiation and survival of hematopoietic cells. 1, 2 Binding of FLT3 ligand (FL) to FLT3 promotes receptor dimerization and activation of FLT3. 1 The activated receptor then activates the phosphotidylinositol 3-kinase (PI3K) and RAS signal-transduction cascades. 3, 4 FLT3 mutations are the most frequent genetic lesion seen in acute myeloid leukemia (AML). Of patients with AML, 15-35% have an internal tandem duplication (ITD) of the juxtamembrane domain of FLT3 (FLT3-ITD) [5] [6] [7] [8] and 5-10% have mutations in the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD). 9, 10 Both types of FLT3 mutation result in ligandindependent activation of the receptor and activation of downstream signaling pathways. [11] [12] [13] The presence of FLT3-ITD is associated with leukocytosis and poor clinical outcome in both pediatric and adult patients with AML. 7, 8, 14, 15 b-catenin is a multifunctional protein that plays an important role in both cell -cell interactions 16, 17 and transcriptional regulation. [18] [19] [20] In epithelial cells, b-catenin is localized at the inner surface of the plasma membrane, where it functions in conjunction with E-cadherin as part of the adherens junction, a specialized cytoskeletal complex that regulates cell-cell adhesion. 21 b-catenin is also the critical effector of the canonical Wnt signaling pathway, in which nuclear b-catenin coactivates transcription in association with LEF/TCF family members. In the absence of secreted Wnts, the modular protein axin provides a scaffold for the binding of glycogen synthase kinase-3b (GSK3b), adenomatous polyposis coli (APC) protein and b-catenin. This facilitates serine/threonine phosphorylation in the N terminus of b-catenin by GSK-3b and subsequent degradation of b-catenin by a proteasome-dependent process. 22, 23 Wnt stimulation leads to b-catenin stabilization, nuclear accumulation and interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to regulate genes important for proliferation and survival. 18, [24] [25] [26] Wnt/b-catenin has previously been implicated in the development of several hematologic malignancies. [27] [28] [29] [30] [31] Recently, it was reported that TCF-dependent transcriptional activity of FLT3-ITD cells is higher than in FLT3-WT cells, suggesting that aberrant b-catenin signaling may contribute to FLT3-ITD-related myeloid transformation. 32 However, the relationship between FLT3 activity and activation of b-catenin-dependent nuclear signaling has not been elucidated. While serine/threonine phosphorylation facilitates degradation of b-catenin in the proteasome, we and others have demonstrated that tyrosine phosphorylation facilitates b-catenin nuclear localization and enhances b-catenin-associated transcription. 25, 33, 34 Thus far, tyrosine phosphorylation of b-catenin and a potential role for FLT3 in this regulatory event have not been examined in AML. In this study, we have examined the effects of FLT3 mutation or activation on b-catenin tyrosine phosphorylation, subcellular localization and transcriptional activity.
Materials and methods

Antibodies and reagents
FLT3 inhibitor AG1296 was purchased from Calbiochem (San Diego, CA, USA). The FLT3 inhibitor PKC 412 and GSK3b inhibitor SB415286 were purchased from LC Laboratories (Woburn, MA, USA). FLT3 siRNA, b-catenin siRNA and control siRNA were purchased from Dharmacon (Lafayette, CO, USA). Recombinant human FLT3 ligand (FL) and recombinant mouse IL-3 were purchased from R&D systems (Minneapolis, MN, USA). Fetal bovine serum (FBS) was purchased from Gibco-BRL (Gaithersburg, MD, USA). Anti-b-catenin monoclonal antibody was purchased from BD Biosciences (San Jose, CA, USA). Anti-FLT3-antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphotyrosine monoclonal antibody was purchased from Upstate (Charlottesville, VA, USA). Anti-phospho-b-catenin antibody (Ser33/37/Thr41), anti-phospho-GSK3 antibody (Ser21/9), anti-GSK3b antibody and anti-topoisomerase II antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Western blotting blocking reagent was purchased from Roche Applied Science (Indianapolis, IN, USA). GammaBind Plus Sepharose beads and horseradish peroxidase (HRP)-labeled goat anti-mouse and goat anti-rabbit antibodies were purchased from Amersham Biosciences (Uppsala, Sweden). BCA Protein Assay reagent, western blot chemiluminescence reagents and Restore Western Blot Stripping Buffer were purchased from Pierce Chemical Co (Rockford, IL, USA). PVDF membrane was purchased from Bio-Rad Laboratories (Hercules, CA, USA).
Cells
The murine IL-3-dependent myeloid progenitor cell line, 32D, was obtained from the RIKEN cell bank (Tsukuba, Japan) and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1.0 ng ml À1 recombinant murine IL-3. WT, ITD and TKD (D835) FLT3-expressing 32D cell lines were reported previously. [10] [11] [12] 35 MOLM-13, a human AML-M5 cell line with the FLT3-ITD mutation, 6 was kindly provided by Dr Yoshinobu Matsuo (Fujisaki Cell Center, Okayama, Japan). MV 4-11, a human AML cell line expressing FLT3-ITD, and THP-1, a human AML-M5 cell line expressing FLT3-WT, 6 were purchased from ATCC (Manassas, VA, USA). MOLM-13 and THP-1 were maintained in RPMI-1640 medium supplemented with 10% FBS. MV 4-11 was maintained in Iscove's modified Dulbecco's medium (IMDM) with 20% FBS.
Immunoprecipitation and immunoblotting assays. Cells were washed twice with ice-cold PBS, and were lysed in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 50 mM NaF, 1 mM Na 3 VO 4 , 10 mg ml À1 aprotinin, 10 mg ml À1 leupeptin and 1 mM phenylmethylsulfonyl fluoride). After incubation for 1 h at 4 1C, lysates were spun at 12 000 g for 25 min and pellets were discarded. Lysates were immunoprecipitated with each primary antibody overnight at 4 1C. GammaBind Plus Sepharose (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) beads were added and the mixture was rocked for 1 h at 4 1C. The beads were subsequently washed three times with lysis buffer and mixed with sodium dodecyl sulfate (SDS) sample buffer. After boiling for 5 min, samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto PVDF membranes (Millipore, Billerica, MA, USA). The membranes were incubated overnight with primary antibody in 10% blocking reagent in TNE washing buffer: (50 mM NaCl, 10 mM Tris-HCl, pH 7.5, 2.5 mM EDTA, 0.1% Tween 20) . Primary antibodies were detected by HRP-labeled secondary antibody (1:2000) and were visualized using chemiluminescence reagents. For reprobing, the membranes were stripped with stripping buffer and reprobed with the indicated antibodies. Band optical densities were measured using a GS-800 densitometer and Quantity One software (Bio-Rad).
Immunocytochemistry
Cells that had been attached to glass slides by cytocentrifugation (Shandon, Pittsburgh, PA, USA) were fixed with 3.7% formaldehyde in PBS for 10 min and permeabilized with 0.2% Triton X-100 for another 10 min at room temperature. The cells were stained with monoclonal anti-b-catenin antibody (BD Biosciences), Alexa Fluor 488 goat anti-mouse immunoglobulin (Molecular Probes, Carlsbad, CA, USA) and 4 0 ,6-diamidino-2-phenylindole (DAPI; Molecular Probes). The cells were viewed using a Leica DM IRB fluorescence microscope ( Â 100 objective) equipped with a Z-axis motor (Ludl Electronics, Hawthorne, NY, USA). Stacks of images (13-19 optical sections at a step size of 0.3 mm) were taken with a digital camera (Hamamatsu) and processed using Openlab Volume Deconvolution software (Improvision, Lexington, MA, USA). Nuclear b-catenin was determined using the colocalization feature in Openlab. Briefly, the areas of colocalization, depicted as violet, were generated by calculation of measurement statistics based on intensity information in the whole image obtained from two fluorescence channels detecting b-catenin and DAPI.
Preparation of subcellular fractions
Cells were washed and treated with ice-cold low-salt lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM Na 3 VO 4 , 10 mg ml À1 aprotinin, 10 mg ml À1 leupeptin) for 10 min at 4 1C. Cells were homogenized with 15 strokes of a Dounce homogenizer. Homogenates were centrifuged at 700 g for 5 min and supernatant fractions were saved as cytoplasmic extracts. The pellets were resuspended in high-salt lysis buffer (20 mM HEPES, pH 7.9, 25% glycerol, 420 mM NaCl, 1% TritonX-100, 1 mM Na 3 VO 4 , 10 mg ml À1 aprotinin, 10 mg ml À1 leupeptin) and rotated for 10 min at 4 1C. Cellular debris was removed by centrifugation and supernatants were saved as nuclear fractions. Equal amounts of protein were subjected to western blot analysis.
Quantitative Reverse Transcriptase-PCR. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and cDNA was prepared using the TaqMan Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of mRNA expression was carried out by real-time RT-PCR using the ABI Prism 7700 Sequence Detection System (Applied Biosystems). All sample mRNA levels were normalized to the level of 18S ribosomal RNA. The primer and probe sequences for realtime RT-PCR were as follows: rRNA forward 5
In vitro kinase assay anti-b-catenin antibody. Since albumin is not phosphorylated by FLT3, the membrane was stained with Ponceau S to identify the location of albumin.
RNAi-mediated silencing of FLT3
MOLM-13 cells (2 Â 10 6 in 100 ml) were transfected with 1 mM FLT3 siRNA, b-catenin siRNA or control siRNA by electroporation (Nucleofector, Amaxa Biosystems, Gaithersburg, MD, USA).
Following transfection, the cells were incubated for 48 h and then were subjected to immunoprecipitation and immunoblot assay. Band optical density was measured using a GS-800 densitometer and Quantity One software.
Primary AML samples
Bone marrow and peripheral blood samples were obtained from leukemia patients under an Institutional Review Board-approved Figure 1 Tyrosine phosphorylation of b-catenin in FLT-3-expressing cell lines. (a) Cell lysates were obtained as described in 'Materials and methods'. To detect tyrosine phosphorylation of b-catenin, 1 mg of proteins from cell lysates was precipitated using 2 mg of anti-b-catenin antibody. Proteins were resolved by reducing 10% SDS-PAGE, electrotransferred to PVDF membrane and western blotted for anti-phosphotyrosine (upper panel). Membranes were stripped and reprobed with anti-b-catenin antibody (middle panel). Optical density ratio of phosphotyrosine/total b-catenin was measured using a GS-800 densitometer with Quantity One software (lower panel). (b, c) Effect of FLT3 inhibition or activation on b-catenin tyrosine phosphorylation. Cells were treated with or without PKC412 (20 nM for 2 h) or FLT3 ligand (FL; 50 ng ml À1 for 1 h) and then lysed. Protein (1 mg) from cell lysates was precipitated with 2 mg of anti-b-catenin antibody or 1.5 mg of anti-FLT3 antibody. Whole-cell lysates and immunoprecipitated samples were resolved by reducing 7.5% SDS-PAGE, electrotransferred to a PVDF membrane and western blotted with corresponding antibodies. , Amersham) and subjected to centrifugation on Ficoll-Hypaque (Amersham) to remove necrotic cells. Eighty million cells from each sample were split into two aliquots. To one aliquot was added CEP-701 to a final concentration of 50 nM (FLT3 inhibited), while the other aliquot contained dimethylsulfoxide (DMSO) (control). After incubation at 37 1C, cells were divided into two aliquots, pelleted, lysed and immunoprecipitated for either FLT3 or b-catenin. Statistical analysis was performed using StatView software (SAS, Cary, NC, USA).
Results
Tyrosine phosphorylation of b-catenin is increased in activated FLT3-expressing AML cells
Tyrosine phosphorylation of b-catenin in FLT3-expressing cell lines was investigated by immunoprecipitation assay. As shown in Figure 1a (Figure 1c , lower panel). These results suggest that tyrosine phosphorylation of b-catenin, not its serine/threonine phosphorylation or total level, closely parallels FLT3 activation status.
Stabilization of
b-catenin following GSK3b inhibition does not promote enhanced tyrosine phosphorylation of b-catenin To study the relationship between the tyrosine phosphorylation and the total level of b-catenin further, we investigated the effect of GSK3b inhibition on b-catenin tyrosine phosphorylation status. As shown in Figure 2, treatment with the GSK3b inhibitor SB415286 increased the total b-catenin level in THP-1 cell line and decreased b-catenin serine/threonine phosphorylation. However, SB415286 did not increase tyrosine phosphorylation of b-catenin in these cells, rather it decreased the ratio of tyrosine-phosphorylated/total b-catenin.
Silencing of FLT3 gene expression leads to reduced phosphorylation of b-catenin in FLT3-ITD AML cells
We next investigated whether RNAi-mediated knockdown of FLT3 expression affected b-catenin tyrosine phosphorylation similarly to small-molecule FLT3 kinase inhibitors. As shown in Figure 3 , when the expression of FLT3 in MOLM-13 cells was suppressed with FLT3 siRNA, tyrosine phosphorylation of b-catenin was concomitantly reduced, while the total protein level of b-catenin was not changed. In contrast, while the protein level of b-catenin was suppressed by b-catenin siRNA, the ratio of tyrosinephosphorylated/total b-catenin was not significantly affected.
Nuclear localization of b-catenin in activated FLT3-expressing cell lines
Because tyrosine phosphorylation of b-catenin has been reported to be associated with increased nuclear accumulation, 25, 33, 38 we investigated the subcellular localization of b-catenin by immunocytochemistry and western blot. Although b-catenin was located mainly in the cytoplasm in THP-1, it was primarily nuclear in MOLM-13 (Figures 4a and b) . After treatment with PKC412, the amount of nuclear b-catenin was markedly decreased in MOLM-13 cells. Similar to PKC412 treatment, FLT3 siRNA decreased nuclear b-catenin while control siRNA had no effect. In contrast, after treatment of THP-1 cells with FL, the amount of nuclear b-catenin was increased. Western blotting of subcellular fractions confirmed b-catenin to be enriched in the nuclear fraction of cells with active FLT3 signaling (Figure 4c ). These findings suggest that activated FLT3 is associated with increased nuclear accumulation of b-catenin and that nuclear b-catenin is preferentially tyrosine-phosphorylated.
Activation status of FLT3 affects b-catenin target gene expression in AML and 32D cell lines
Because enhanced nuclear localization of b-catenin was correlated with the activation status of FLT3, we wished to determine whether b-catenin-dependent transcription could be affected by FLT3 activity in MOLM-13, THP-1 and 32D transfectants. To examine this question, the mRNA levels of two b-catenin target genes, cyclin D1 and c-myc, were measured using real-time RT-PCR. In cells with FLT3 gain-offunction mutations, PKC412 treatment markedly decreased RNA expression of both c-myc and cyclin D1 (Figure 5a ). In cells with FLT3-WT, expression of c-myc and cyclin D1 was increased after treatment with FL (suggesting functional nuclear localization of b-catenin), while SB415286 had very little effect (Figure 5b ). Similar to PKC412 treatment, FLT3 siRNA decreased expression of cyclin D1, as did b-catenin siRNA (Figure 5c ). Preparation of subcellular fractions is described in Materials and methods. To verify the purity of subcellular fractions and to control for protein loading, blots were reprobed with antibodies to topoisomerase II (Topo II) for nuclear fractions and a-tubulin (tubulin) for cytoplasmic fractions.
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Active FLT3 binds to b-catenin
We used co-immunoprecipitation techniques to investigate the possible physical interaction between FLT3 and b-catenin. In MOLM-13 cells, endogenous b-catenin co-immunoprecipitated with endogenous FLT3. This association was markedly reduced in cells treated with PKC412 (Figure 6a ). In the reciprocal experiment, FLT3 was co-immunoprecipitated by anti-b-catenin antibody in untreated cells, but this association was reduced in PKC412-treated cells (Figure 6b ). In THP-1 cells, although a small amount of b-catenin was co-immunoprecipitated with anti-FLT3 antibody in the absence of FL, the proportion of b-catenin bound to FLT3 was increased after FL treatment (Figure 6a ). This observation was confirmed by coimmunoprecipitation with anti-b-catenin antibody (Figure 6b ). These results demonstrate that active FLT3 preferentially binds to b-catenin, whether the kinase is mutated or not, and that inhibition of FLT3 activation decreases interaction between FLT3 and b-catenin.
Active FLT3 kinase phosphorylates b-catenin directly
To determine whether active FLT3 can directly phosphorylate tyrosine residues of b-catenin, we performed an in vitro kinase assay using recombinant active FLT3 as enzyme source and recombinant b-catenin as substrate. As shown in Figure To determine whether these observations are of clinical relevance, we investigated the effect of FLT3 inhibition on the tyrosine phosphorylation status of b-catenin in mononuclear cells of AML patients. Four individual isolates of bone marrow mononuclear cells obtained from patients harboring the FLT3-ITD mutation were treated ex vivo with the FLT3 inhibitor CEP-701 (50 nM). As shown in Figure 7 , this treatment markedly reduced the level of FLT3 phosphorylation (P ¼ 0.0046). In each case, tyrosine phosphorylation of b-catenin was concomitantly reduced in a time-dependent manner (P ¼ 0.043).
Discussion
Wnt signaling is required for normal hematopoiesis, and deregulated Wnt signaling has been implicated in the etiology and progression of several hematologic malignancies. [27] [28] [29] [30] [31] Wnt effector b-catenin is expressed in both lymphoid and myeloid leukemia cell lines and primary cells. Inhibition of Wnt/ b-catenin signaling in Jurkat T-lymphoblastic cells impaired proliferation and increased susceptibility to apoptosis in response to Fas ligation. 28 In multiple myeloma (MM), b-catenin protein was found to be overexpressed, and stimulation by various Wnts led to its accumulation and nuclear translocation accompanied by cell proliferation. 29 In colorectal cancer, truncation or loss of the APC protein, or mutation of the GSK3b phosphorylation sites in b-catenin, is thought to be critical mechanism underlying b-catenin cytoplasmic and nuclear accumulation, promoting the expression of b-catenin-regulated pro-proliferative and survival genes. 20, 39 However, Wnt signaling was reported to be increased in AML and MM without mutation of APC or b-catenin, 29, 31 suggesting that alternative mechanisms might contribute to b-catenin deregulation in hematologic malignancies. Recently, Wnt-independent signaling has been suggested to cooperate with FLT3 in myeloid transformation. Protein expression and activity of b-catenin in fostering TCF/LEF-dependent transcription were increased in FLT3-ITD-32D cells independent of extracellular Wnt ligand. 32 However, the mechanism underlying this phenomenon has remained unclear.
Tyrosine phosphorylation of b-catenin has been studied not only for its impact on the physical association between bcatenin and E-cadherin but also for its relationship to b-catenindependent TCF transcriptional activity. Phosphorylation of Tyr-142 and Tyr-654 on b-catenin promotes its release from E-cadherin and its accumulation in the cytoplasm. 25, 40, 41 Since b-catenin has been shown to freely equilibrate between the FLT3 regulates b-catenin tyrosine phosphorylation in AML T Kajiguchi et al nucleus and the cytoplasm, its retention in one location or the other appears to be mediated by association with other proteins. 42 Tyrosine-phosphorylated b-catenin preferentially associates with the BCL9 homolog BCL9-2, which promotes its nuclear retention and association with TCF, 43 thereby stimulating TCF-driven transcriptional activity. 25, 33, 38, 40 Although it has been reported that several tyrosine kinases phosphorylate b-catenin in vivo or in vitro (for example, Src kinase, 44 ErbB2 33 and oncogenic mutants of RON and MET 26, 45 ), there has been no investigation of FLT3 in this regard, nor of other tyrosine kinases in hematologic malignancies.
In the current study, we investigated the relationship between Although FLT3 activates PI3K 3,4 and signaling via PI3K/AKT stabilizes b-catenin protein level through inhibition of GSK3b, 22, 23, 38 use of a GSK3b inhibitor revealed that FLT3-dependent regulation of tyrosine phosphorylation of b-catenin is not mediated by FLT3 activation of the PI3K/AKT axis. These data suggest that two mechanisms might exist to regulate b-catenin in FLT3-AML cells: (1) b-catenin protein stabilization via PI3K/AKT and (2) b-catenin tyrosine phosphorylation mediated directly by FLT3 kinase. Taken together, our data strongly suggest that tyrosine phosphorylation of b-catenin by FLT3 is one of the principal mechanisms by which FLT3 activates b-catenin signaling, and that enhanced nuclear b-catenin signaling promotes malignant transformation associated with activating FLT3 mutations.
Recently, deregulated nuclear b-catenin signaling has been reported in a wide range of hematologic malignancies. It is therefore of interest that over 40 chromosomal translocations leading to deregulation of at least 12 protein tyrosine kinases have been reported in hematologic malignancies, including, for example, the deregulated tyrosine kinase activities associated with the oncogenic fusion proteins BCR/ABL and NPM/ALK. 46 Indeed, BCR/ABL has been shown to promote the tyrosine phosphorylation and enhanced transcriptional activity of b-catenin in chronic myelogenous leukemia, and b-catenin silencing inhibited proliferation of these cells. 47 Further, the efficacy of disrupting the b-catenin/TCF transcriptional complex as a therapeutic approach in treating multiple myeloma has very recently been reported. 48 Thus, enhanced b-catenin nuclear retention and signaling may be a shared downstream event among various hematologic malignancies and b-catenin is suggested to be a significant therapeutic target in these neoplasms. optical density ratios of phosphotyrosine/FLT3 and phosphotyrosine/bcatenin were obtained using a GS-800 densitometer with Quantity One software, and statistical analysis was performed using StatView software.
FLT3 regulates b-catenin tyrosine phosphorylation in AML T Kajiguchi et al
